Home
About
Team
News
Portfolio
Contact Us
Our
News
Archive for September, 2022
Disrupters: Jonathan Steckbeck
September
30 ,
2022
|
Posted by admin
|
In:
Uncategorized
Categories
News
Uncategorized
Recent Posts
PEPTILOGICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B STUDY OF PLG0206 FOR PERIPROSTHETIC JOINT INFECTION
Disrupters: Jonathan Steckbeck
PEPTILOGICS RECEIVES FDA FAST TRACK DESIGNATION FOR PLG0206, AN INVESTIGATIONAL PEPTIDE THERAPEUTIC IN DEVELOPMENT FOR THE TREATMENT OF PERIPROSTHETIC JOINT INFECTION
Peptilogics proposed treatment for joint infection moves forward
In Her Own Words: Covid propels Teresa Whalen to improve cancer treatment
Archives
October 2022
September 2022
July 2022
April 2022
February 2022
January 2022
December 2021
September 2021
August 2021
January 2021
December 2020
September 2020
August 2020
July 2020
June 2020
May 2020
April 2020
March 2020
August 2019
July 2019
April 2019
February 2019
January 2019
November 2018
October 2018
August 2018
March 2018
February 2018
January 2018
December 2017
October 2017
September 2017
August 2017
March 2017
December 2016
October 2016
June 2016
December 2015
November 2015
October 2015
September 2015
August 2015
May 2015
January 2015
July 2014
May 2014
